FDA denies request for expedited approval of Alzheimer’s drug
By
John Roszkowski
Jan 23, 2023
The Food and Drug Administration late last week denied Ely Lilly’s request for expedited approval of the Alzheimer’s drug donanemab, citing the need for more clinical trials to test the safety and...
Study seeks to shed light on COVID-19’s impact on the brain
By
John Roszkowski
Sep 23, 2022
A global consortium of researchers is seeking to uncover the short-term and long-term impacts of COVID-19 on the brain to assess whether it can lead to cognitive impairments later in life such as Alzheimer’s...